N Dauletbaev
Overview
Explore the profile of N Dauletbaev including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dauletbaev N, Herscovitch K, Das M, Chen H, Bernier J, Matouk E, et al.
Br J Pharmacol
. 2015 Jul;
172(19):4757-71.
PMID: 26178144
Background And Purpose: There is current interest in vitamin D as a potential anti-inflammatory treatment for chronic inflammatory lung disease, including cystic fibrosis (CF). Vitamin D transcriptionally up-regulates the anti-inflammatory...
2.
Herscovitch K, Dauletbaev N, Lands L
Paediatr Respir Rev
. 2013 Dec;
15(2):154-62.
PMID: 24332502
Cystic fibrosis (CF) is characterized by chronic infection and inflammation in the airways that lead to progressive lung damage and early death. Current anti-inflammatory therapies are limited by extensive adverse...
3.
Lands L, Iskandar M, Beaudoin N, Meehan B, Dauletbaev N, Berthiuame Y
J Med Food
. 2010 Feb;
13(1):77-82.
PMID: 20136439
Cystic fibrosis (CF) is characterized by malnutrition, chronic pulmonary inflammation, and oxidative stress. Whey protein is rich in sulfhydryl groups and is recognized for its ability to increase glutathione and...
4.
Dauletbaev N, Fischer P, Aulbach B, Gross J, Kusche W, Thyroff-Friesinger U, et al.
Eur J Med Res
. 2009 Aug;
14(8):352-8.
PMID: 19666395
Objective: We conducted a single-centre, randomised, double-blinded, placebo-controlled phase II clinical study to test safety and efficacy of a 12-week therapy with low-dose (700 mg/daily) or high-dose (2800 mg/daily) of...
5.
Dauletbaev N, Viel K, Buhl R, Wagner T, Bargon J
J Cyst Fibros
. 2004 Oct;
3(2):119-24.
PMID: 15463894
Background: Reduced glutathione (GSH) is a major antioxidant in the lung. In cystic fibrosis (CF) patients, extracellular GSH levels of lower airways, obtained by bronchoalveolar lavage (BAL), were reported to...
6.
Turchanowa L, Dauletbaev N, Milovic V, Stein J
Eur J Clin Invest
. 2001 Dec;
31(10):887-93.
PMID: 11737227
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit colonic tumourigenesis and have an established usefulness in cancer prevention. Because polyamines are essential for neoplastic cell growth, the aim of this study was...
7.
Dauletbaev N, Rickmann J, Viel K, Buhl R, Wagner T, Bargon J
Thorax
. 2000 Dec;
56(1):13-8.
PMID: 11120898
Background: Glutathione is central to the antioxidant defences of the lung. The aim of this study was to determine whether sputum induction can be used for the measurement of glutathione...
8.
Frye M, Bargon J, Dauletbaev N, Weber A, Wagner T, Gropp R
J Clin Pathol
. 2000 Nov;
53(10):770-3.
PMID: 11064671
Background/aims: Human defensins are antibiotic peptides expressed in myeloid and epithelial cells. Human alpha-defensin 5 (HD5) has been detected in Paneth cell granules in the crypts of Lieberkühn and has...
9.
Bargon J, Dauletbaev N, Kohler B, Wolf M, Posselt H, Wagner T
Respir Med
. 1999 Dec;
93(11):835-8.
PMID: 10603634
Aspergillus colonization is a common phenomenon in adult cystic fibrosis (CF) patients. The clinical significance of Aspergillus for the pathogenesis of CF lung disease remains unclear and factors predisposing to...
10.
Dauletbaev N, Viel K, Behr J, Loitsch S, Buhl R, Wagner T, et al.
Eur Respir J
. 1999 Dec;
14(5):1150-5.
PMID: 10596705
Inhaled corticosteroids have been proposed to decrease pulmonary inflammation in cystic fibrosis (CF). In this study the effects of therapy with inhaled fluticasone on clinical and sputum outcomes (leukocyte count,...